US medspa industry report 2026 — 10,488 locations, $9.46B market, state-by-state growth analysis

How the US medspa industry reached 10,488 locations

The most-cited number in every US medspa boardroom in 2026 is 10,488. That is the AmSpa 2026 State of the Industry location count for medical spas operating across the United States, and it is the number that finally crossed the five-figure threshold the sector had been circling for three years. The 2017 count, for a reasonable historical benchmark, was approximately 4,200 locations. The trajectory in the eight intervening years is one of the fastest greenfield builds inside the entire US healthcare services economy.

The build is not evenly distributed. The three drivers that produced the 150% expansion — injectable neuromodulator adoption in the female 35-64 demographic, minimally-invasive body-contouring device deployment, and physician-supervised nurse-practitioner and physician-assistant delivery models — all favor the same geographic profile. High-income metros in the sun-belt with a large concentration of aesthetically-attuned professional consumers dominate the count. Cold-weather secondary metros exist on the map but are meaningfully underweighted.

The ownership mix is where the story of the next five years will be written. Independents — a single physician-owner or a single non-physician owner with a supervising physician of record — still form the majority of the 10,488 locations. But the growth rate in franchised concepts and in physician-backed multi-unit rollups has run ahead of the growth rate in single-location independents for the last three consecutive years. IBISWorld industry outlooks for the sub-sector consistently flag consolidation as the defining pressure through 2029.

Why 150% growth in eight years

The 2017-2026 growth curve is not a single trend line, it is three overlapping ones. First, injectable neuromodulators (botulinum toxin type A products) moved from a coastal-and-affluent adoption pattern to a broadly national one, unlocking a much larger addressable customer base per capita. Second, energy-based devices — radiofrequency, laser resurfacing, cryolipolysis, focused ultrasound — matured to the point where a single medspa footprint could offer a full skin-and-body menu without a hospital-grade capital budget. Third, state boards clarified delegation rules for non-physician injectors under physician supervision, expanding the labor pool from a scarce physician-only bottleneck to a more scalable NP-and-PA workforce.

Each of those three shifts individually would have produced growth. Overlapping in the same eight-year window, they produced 150%.

Market size, growth curve and treatment mix

The US medical aesthetics market is USD 9.46 billion in 2026, per the MarketsAndMarkets forecast base for the sector. The compound annual growth rate through 2031 is 13%, taking the market to approximately USD 17.45 billion at that horizon. That is a doubling in five years, which in a health-services sub-vertical is exceptional. Only a handful of other US healthcare sub-verticals — dental service organizations, direct-to-consumer telehealth verticals in specific therapeutic areas, and digital behavioral health — are in the same growth bracket.

Treatment mix is where the operator economics live. Facial treatments account for approximately 55% of medspa revenue in 2026, a number that has been remarkably stable over the last three years even as the location count has expanded. Body contouring, energy-based skin resurfacing, hair reduction, and wellness services (IV therapy, hormone optimization, weight-loss medication management) make up the remainder in that order.

Why facial stays at 55% even as body contouring scales

The instinctive read on the treatment mix is that body contouring should be growing its share as new devices launch and price points normalize. What is actually happening is the opposite: facial holds share because the injectable customer is a recurring-revenue customer on a 12-week to 16-week retreatment cadence, while body-contouring customers — even satisfied ones — are on a much longer effective retreatment interval. Operators that have tried to shift their mix toward body contouring at the expense of injectables have consistently seen revenue per chair per year fall, not rise.

The strategic implication for a growth plan is that the facial injectable line item should almost always be the acquisition engine, with body contouring as the higher-ticket add-on rather than the lead treatment.

GLP-1 medication management as a 2026 wildcard

The single fastest-moving category in the 2026 mix is physician-supervised medical weight management using GLP-1 agonists. What began as a specialist offering has moved rapidly into the medspa channel wherever the state medical board has clarified the supervision and prescribing rules. This is a category with a distinctive marketing profile — monthly recurring revenue, high customer LTV, but also a compliance envelope that requires careful state-board review before scale.

Federal and state compliance stack for US medspa marketing

Every US medspa marketing plan has to clear two compliance layers before spend: federal, and state. The federal envelope has six statutory anchors that matter for medspa advertising. State overlay is set by the state medical board and, where applicable, the state nursing board, and it varies far more than most operators expect.

HIPAA — where a medspa becomes a covered entity

A medspa is a HIPAA covered entity from the moment it transmits any health information electronically in connection with a HIPAA transaction — for most operators, that is the first electronic insurance eligibility check or the first electronic prescription. In practice, essentially every US medspa in 2026 is a covered entity. That means the Privacy Rule marketing provisions at 45 CFR 164.501 apply, the tracking-technology guidance issued by the Office for Civil Rights in December 2022 and updated in March 2024 applies, and any vendor touching Protected Health Information needs an executed Business Associate Agreement under 45 CFR 164.504(e).

The single most common finding in an ICG US medspa compliance audit is a tag on the appointment-booking flow that forwards specialty and IP data to a non-BAA ad platform. Fix that surface first.

TCPA — the SMS envelope that has teeth

SMS is the highest-converting medspa channel and also the highest-liability. TCPA statutory damages sit at USD 500 to USD 1,500 per unsolicited message under 47 USC 227. A single class action can and does reach nine figures. The 2026 baseline is: prior express written consent for marketing, functioning STOP handling, quiet-hours compliance to recipient time zone, and documented consent capture. Buy a consent management platform if you don’t already run one.

FTC 16 CFR §255 — endorsements, before/after and influencers

Before/after imagery and influencer content is where medspa marketing collides with the FTC endorsement guides most often. Every material connection between the practice and the endorser must be disclosed. Typical-results disclaimers are not a substitute for actually typical results. The 2023 revision to the guides sharpened the position on hidden compensation and on artificially amplified reviews.

FDA 21 CFR §202.1 — brand mentions of prescription products

Brand-name references to prescription neuromodulators or fillers in marketing content trigger FDA advertising rules — fair balance, brief summary or reference to full prescribing information, and either full-scope or reminder-ad formats. The safest default is treatment-category messaging rather than brand-name messaging for programmatic reach, with brand-name creative reserved for permission-based channels where compliant fair-balance can be delivered.

State medical board rules — ten-state matrix

The state overlay on federal rules is where a plan that works in Texas can be non-compliant in California, and vice versa. The matrix below summarizes the top-ten aesthetic states on three dimensions that most often affect a marketing plan: physician-ownership requirement, non-physician injector delegation, and advertising-specific board rules.

Where a US medspa should actually spend media in 2026

The channel mix a US medspa should run in 2026 is a function of three inputs: metro density, treatment mix, and the maturity of the practice’s own review base and content library. The generalized mix below is a starting point, not a prescription.

The AIO capture layer

AI Overviews now sit above the traditional blue-link result set for a growing share of medspa-adjacent queries. The AIO layer is not a paid layer — it is an earned layer that requires depth of on-page copy, clean schema (Report, Article, Person, MedicalProcedure, FAQPage), and speakable-marked H2s. Every ICG US medspa engagement in 2026 includes an AIO capture plan as a first-class deliverable alongside traditional search and social.